BioSpace News Archive

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that it will host a virtual R&D Day on Tuesday, December 7, 2021 from 10:00 a.m. to 12:00 p.m. ET.

Immunic, Inc. (Nasdaq: IMUX), today announced the first patient enrolled in its phase 3 ENSURE program of lead asset, vidofludimus calcium (IMU-838), the company’s selective oral DHODH inhibitor, in patients with relapsing multiple sclerosis (RMS).

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced the appointment of Jonathan J. Birchall as Chief Commercial Officer.

Science Applications International Corp. received $348 million in contract awards from space and intelligence community organizations for the third quarter of fiscal year 2022.

City of Hope, a world-renowned research and treatment organization for cancer, diabetes and other life-threatening diseases, announced the opening of a first-in-human clinical trial evaluating the use of a cancer-killing oncolytic virus to treat patients with metastatic triple-negative breast cancer.

Bayer presented new analyses of data from the comprehensive Phase III finerenone clinical trial program, which analyzed KERENDIA® (finerenone) – the first nonsteroidal mineralocorticoid receptor antagonist (MRA)2,3 – versus placebo and in addition to standard of care on cardiovascular (CV) outcomes, including hospitalization for heart failure (HF), across a spectrum of chronic kidney disease (CKD) severity in patients with type 2 diabetes (T2D).

CPhI Worldwide (9-11 November, 2021), which held its first in-person event since 2019, hosted the global pharma community at the Fiera Milano, Milan, welcoming exhibitors and attendees from 146 countries.

AB Science SA (Euronext - FR0010557264 - AB) today announced that it has received authorization from the United States Food and Drug Administration (FDA) to resume patient enrollment in the confirmatory Phase 3 study of masitinib (AB19001) in patients with amyotrophic lateral sclerosis (ALS).

GENFIT is proud to announce that NIS4® technology’s utility has been recognized in a Stage 1 study1 undertaken by the Non-Invasive Biomarkers of Metabolic Liver Disease initiative of the Foundation for the National Institutes of Health’s Biomarkers Consortium as demonstrating a unique performance in identifying patients with “at-risk” Non-Alcoholic Steatohepatitis.

QurAlis Corporation, a biotech company developing breakthrough precision medicines for amyotrophic lateral sclerosis and other neurodegenerative diseases with genetically validated targets, announced that its CEO and co-founder, Kasper Roet, PhD, will present an update about the company at the 33rd Annual Piper Sandler Virtual Healthcare Conference.